BioMarin to Present at Two Upcoming Investor Conferences in New York
- 2014 Citi Global Healthcare Conference
- 2014 RBC Capital Markets' Global Healthcare Conference
SAN RAFAEL, Calif., Feb. 19, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical
Inc. (Nasdaq:BMRN) today announced that the company will participate in two
upcoming investor conferences.On February 25^th, Henry Fuchs, M.D., Executive
Vice President and Chief Medical Officer, will participate on a breast cancer
panel at the 2014 Citi Global Healthcare Conference. On February 26^th, Dr.
Fuchs and Dan Spiegelman, Executive Vice President and Chief Financial Officer
will participate in a fireside chat at the 2014 RBC Capital Markets' Global
Healthcare conference at 8:30am ET. To access the live webcast of the RBC
presentation, please visit the Investor section of the BioMarin website,
www.BMRN.com. A replay will be also archived on the site for at least one week
following the event.
BioMarin develops and commercializes innovative biopharmaceuticals for serious
diseases and medical conditions. The company's product portfolio comprises
five approved products and multiple clinical and pre-clinical product
candidates. Approved products include VIMIZIM™ (elosulfase alfa) for MPS IVA;
Naglazyme® (galsulfase) for MPS VI, a product wholly developed and
commercialized by BioMarin; Aldurazyme® (laronidase) for MPS I, a product
which BioMarin developed through a 50/50 joint venture with Genzyme
Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria
(PKU), developed in partnership with Merck Serono, a division of Merck KGaA of
Darmstadt, Germany and Firdapse® (amifampridine), which has been approved by
the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome
(LEMS).Product candidates include PEG PAL (PEGylated recombinant
phenylalanine ammonia lyase), which is currently in Phase 3 clinical
development for the treatment of PKU, BMN 673, a poly ADP-ribose polymerase
(PARP) inhibitor, which is currently in Phase 3 clinical development for the
treatment of germline BRCA breast cancer, BMN 701, a novel fusion protein of
insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is
currently in Phase 1/2clinical development for the treatment of Pompe
disease, BMN 111, a modified C-natriuretic peptide, which is currently in
Phase 1 clinical development for the treatment of achondroplasia and BMN 190,
a recombinant human tripeptidyl peptidase-1 (rhTPP1) for the treatment of
late-infantile neuronal ceroid lipofuscinosis (CLN2), a form of Batten
Disease, which is currently in Phase 1, BMN 270, an AAV-factor VIII vector,
for the treatment of hemophilia A and BMN 250, a novel fusion of
alpha-N-acetyglucosaminidase (NAGLU) with a peptide derived from insulin-like
growth factor 2 (IGF2), for the treatment of MPS IIIB. For additional
information, please visit www.BMRN.com. Information on BioMarin's website is
not incorporated by reference into this press release.
BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. Logo
Press spacebar to pause and continue. Press esc to stop.